WO1993005177A1 - In situ hybridization method - Google Patents
In situ hybridization method Download PDFInfo
- Publication number
- WO1993005177A1 WO1993005177A1 PCT/JP1992/001128 JP9201128W WO9305177A1 WO 1993005177 A1 WO1993005177 A1 WO 1993005177A1 JP 9201128 W JP9201128 W JP 9201128W WO 9305177 A1 WO9305177 A1 WO 9305177A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probe
- reporter
- complex
- nucleic acid
- labeled
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a diagnostic method for performing in situ hybridization with double-stranded DNA targets .
- In situ hybridization employs direct hybridization of a DNA probe with DNA or RNA in biological structures, typically permeabilized cells, subcellular fractions, or fixed chromosome preparations. Because the method can yield morphological information about the localization of specific-sequence target nucleic acid(s) in fixed
- in situ hybridization is directed toward a target sequence in a double-stranded duplex nucleic acid, typically a DNA duplex associated with a pathogen or with a selected sequence in viral or cell chromosomal DNA.
- a single-stranded labeled probe is added to the permeabilized structure, which has been heated to a temperature sufficient to denature the target duplex nucleic acid, and the probe and denatured nucleic acid are allowed to react under suitable hybridization, or reannealing conditions.
- the structure After removal of unbound (non-hybridized) probe, the structure is processed for examination for the presence of reporter label, allowing the slte(s) of probe binding to target duplex nucleic acid to be localized in the biological structure, i.e., in the context of cell or subcellular morphology.
- the method has been widely applied to chromosomal DNA, for mapping the location of specific gene sequences, and distances between known gene sequences (Lichter, Meyne, Shen), for studying chromosomal distribution of satellite or repeated DNA (Weier, Narayanswami, Meyne, Moyzis, Joseph, Alexandrov), for examining nuclear organization (Lawrence, Disteche, Trask), for analyzing chromosomal aberrations (Lucas), for localizing DNA damage in single cells or tissue (Baan) and for
- biotinylated probes using digital image analysis to study interphase chromosome topography (Emmerich).
- hybridization method is for detecting the presence of virus in host cells, as a diagnostic tool (Unger, Haase, Noonan, Niedobitek, Blum).
- PCR polymerase chain reaction
- the in situ hybridization method described above has a number of limitations. The most serious limitation is the requirement for denaturing the duplex target DNA, to form the necessary single-stranded form of the target. Denaturation typically is performed by heating the sample or treating with chemicals and heat. The heat treatment can produce spurious and unwanted changes in the nucleic acid being examined, related to structural changes and nucleic acid reassociation with repeated sequences within the DNA.
- the repeated DNA sequences can randomly
- the step also adds to the time and effort required in the method.
- the method is limited, by renaturation kinetics, to long renaturation times. Even then, the method may be incapable of producing probe/target renaturation events at low target
- the present invention includes a method of
- the method includes adding to the structure, a probe complex composed of RecA protein stably bound to a single- stranded, reporter-labeled nucleic acid probe which is complementary to one of the strands of the duplex target sequence, under conditions in which the complex can contact the duplex nucleic acid.
- the complex is allowed to bind to the target sequence under non-denaturing conditions. After removing unbound complex, the
- the complex is preferably stabilized by preparation in the presence of ATP ⁇ S.
- the probe may be labeled with a detectable reporter, such as a radiolabel, enzyme or fluorescence tag, or with a ligand, such as biotin or digoxigenin, which can be subsequently reacted with a reporter molecule specific for the ligand, and carrying a detectable reporter.
- the complex may also be stablized using other cofactors including, but not limited to, ATP ⁇ S, GTP ⁇ S, ATP, dATP and a combination of ATP ⁇ S and ADP.
- the method is used for detection and localization of genomic sequence(s) in fixed chromosome DNA structure(s) in metaphase spreads.
- the microscopic ultrastructure of the chromosomes is determined, for example, by fluorescence microscopy, using fluorescence banding patterns.
- the location of the bound complex in relation to the known ultrastructure is then determined independently, for example, by a fluorescence-labeled probe complex whose fluorescence excitation wavelength is different from that of the chromosome banding fluorescence.
- fixed cells or cellular structures are probed in
- the method can be used for detecting the presence of virus or integrated virus-specific genomic sequences in a host cell.
- the binding of a fluorescence-labeled probe to the virus sequence may be determined by fluorescent microscopy or fluorescence activated cell sorting (FACS) or a light or fluorescent or laser scanning microscope. Where an enzyme label is used a light microscope can be used to visualize colored (e.g., black) peroxidase or alkaline phosphatase product produced by the reporter enzyme.
- Such known viral nucleic acid targets include known DNA viruses (such as hepatitis B virus) or RNA viruses that can have a detectable duplex nucleic acid phase in their life cycle. In this method, the fixed structures or
- substructures can be incubated in 10 mM Tris-acetate buffer, pH7.5, at 55-60oC before the addition of the RecA probe complex in order to Increase reaction efficiency: this step does not denature the cellular DNAs.
- the present invention also includes a method of detecting a single copy nucleic acid sequence, typically a duplex DNA sequence, contained in a cellular or
- a probe complex (composed of RecA protein stably bound to a single-stranded, reporter-labeled probe which is complementary the single-copy nucleic acid target sequence) is added to the cellular structure or
- the complex is then allowed to bind to the target sequence under non- denaturing conditions. Unbound complex is then removed from the structure and the structure is examined for the presence of the reporter-labeled probe bound to the nucleic acid.
- the cellular structures or substructures can be fixed and analyzed in solution or on slides.
- the fixing can also include incubatation of the fixed
- the complex can be bound to the target
- the method of the present invention can also include the addition of accessory proteins, such as single-strand binding protein (SSB), topoisomerase I or topoisomerase II.
- accessory proteins such as single-strand binding protein (SSB), topoisomerase I or topoisomerase II.
- kits containing components useful to carrying out the methods described above may include (i) a probe derived from the viral DNA sequences, (ii) RecA protein effective for coating the probe, and (iii) means of detecting the binding of the probe to the known viral DNA in a sample.
- kits may also include RecA-protein coated DNA.
- Figures 1A and 1B are fluorescence photomicrographs of chromosome X alpha satellite DNA probe used for detection of decondensed or partially decondensed alpha satellite chromosomal centromeric DNA target sequences in native, nondenatured (1A) and heat-denatured (1B)
- Figures 2A and 2B are fluorescence photomicrographs of alpha satellite DNA probe to chromosome 7 used for detection of decondensed chromosomal centromeric DNA target sequences in native, nondenatured (2A) and heat- denatured (2B) fixed nuclei in interphase HEp-2 cells;
- Figures 3A and 3B are photomicrographs taken under fluorescence microscopy (3A) and phase microscopy (3B), at the same focus, showing the distribution of chromosome X alpha satellite DNA in a dividing fixed HEp-2 cell nucleus.
- FIGS. 4A-4D illustrate steps for gene localization on a chromosome, employing the method of the invention
- Figures 5-10 show various types of chromosomal aberrations (upper frames A), and the corresponding fluorescence pattern which would be seen with such aberrations (lower frames B); and
- FIGS 11A-11C illustrate the steps in detecting virus infection of cells, by fluorescence activated cell sorting, in accordance with the invention.
- Figure 12 presents a photograph of a cell
- FIGS 13A to 13F show RecA-mediated native
- Figures 14A to 14D show RecA-mediated native fluorescence in situ hybridization detection of unique p53 gene sequences in ATCC HEp-2 cell nuclei on slides.
- FIGS 15A to 15E show RecA-mediated native
- HBV Hepatitis B Virus
- Figures 16A to 16C show specificity of HBV target detection using RecA-mediated native fluorescence in situ hybridization detection in human HCC cells tested by competition hybridization.
- This section describes the basic methodology of in situ hybridization, in accordance with the invention, as applied to various biological structures containing a duplex DNA target with a repeated or unique specific basepair sequence.
- the method of the invention is designed for
- detecting, by complementary-basepair hybridization, a selected target sequence in a biological structure contain a duplex nucleic acid, usually a DNA/DNA duplex nucleic acid.
- the biological structure is any
- morphologically distinct structure such as a cell, sperm, parasite, subcellular fraction or chromosomal preparation containing the target nucleic acid.
- the target duplex in the structure is typically chromosomal DNA, or nucleic acid duplex material
- a viral, parasitic or bacterial pathogen such as virus particles composed of viral duplex genome encapsulated or released from being encapsulated in viral coat proteins.
- Methods of preparing fixed biological structures, such as cells, nuclei, and chromosomal preparations generally follow those used in conventional in situ hybridization by DNA duplex denaturation and reannealing.
- the cellular compartment and DNA structure may be further, fixed or permeabilized by treatment with an organic solvent and acid or cross-linking agent to fix the structural components in their natural morphological relationship.
- organic solvent and acid or cross-linking agent include acetic acid, salts, methanol, formalin, paraformaldehyde, and
- tissue sample may be prepared for slide presentation by embedding in wax or by freezing, followed by sectioning into thin slices.
- the biological material is treated with one or more of a number of agents capable of
- deproteinizing and/or delipidizing the structures can involve the use of proteases, Upases, acid, organic solvents including alcohols, detergents or heat denaturation or combinations of these treatments.
- a common treatment involves one or more washes with
- pretreatments may be useful in reducing background, such as use of inhibitors of non-specific binding of nucleic acids.
- prehybridization with non-specific carrier DNA e.g. salmon sperm
- RNA e.g. tRNA
- Cellular structures of interest may be individual cells, obtained for example from cell culture, cells present in a tissue section or body fluid. Typically, cellular structures from a tissue are sectioned
- Cellular structures may be studied to determine intracellular localization of genomic target sequence(s), or for detecting the presence and/or localization of an Infective organism, such as virus, bacteria, or parasite in the cells.
- mitochondria can be prepared by conventional
- fractionation methods such as isopycnic centrifugation, to obtain subcellular material in enriched or
- the enriched structure preparation may be permeabilized and
- deproteinized as above, probed either in solution or affixed to a slide, as by drying.
- the cells may be pretreated with 75 mM KCl, followed by treatment with methanol:acetic acid, to remove cytoplasm. This fraction, after purification may be further treated for probe hybridization. This method is illustrated in Examples 3-4 and 12-14 for the preparation of HEp-2 cell nuclei for in situ
- HEp-2 cells were pelleted by low-speed centrifugation and the pellet was
- PBS buffered saline
- the preparation may contain the entire set of genomic chromosomes from the cell, such as the preparation in Figures 1A and 1B, or individual, isolated chromosomes, such as can be obtained by
- the chromosomes are generally treated with methanol:acetic acid, placed on a slide, then affixed to the slide with drying.
- parasites isolated from cell or blood samples such as virion particles
- the probe used in the method is a single-stranded nucleic acid, usually a DNA strand probe, or derived by denaturation of a duplex probe, which is complementary to one (or both) strand(s) of the target duplex nucleic acid.
- the probe sequence preferably contains at least 90-95% sequence homology with the target sequence, to insure sequence-specific hybridization of probe and target.
- the single-stranded probe is typically about 100-600 bases long, although a shorter or longer
- polynucleotide probe may also be employed.
- the probe may be constructed or obtained by one of a number of standard methods. Many probes, such as various satellite DNA sequences are commercially available in single-stranded or double-stranded form, other probes can be obtained either directly from viruses, plasmids and cosmids or other vectors carrying specific sequences, or, if desired, by restriction digest of the source of the probe DNA, such as a vector, followed by
- Probes obtained in this manner are typically in double-stranded form, but may, if required, be subcloned in single-stranded vectors, such as an M13 phage vector.
- the probe may be prepared in single- stranded form by oligonucleotide synthesis methods, which may require, for larger probes, forming subfragments of the probe, then piecing the subfragments together.
- the probe is labeled with a reporter or ligand or moiety which allows detection of the targeted sequence in situ.
- the reporter is a radiolabel, such as 32 P-labeled probe formed, for example by nick translation or polymerase chain reaction in the presence of labeled nucleotides.
- the probe may be labeled with one of a selection of fluorescence groups, such as FITC, BODIPY, Texas Red, or Cascade Blue which is
- the groups are derivatized to 3' or 5' probe ends or by incorporation or reaction at internal
- the probes may be labeled with a ligand-type reporter, such as biotin (Weier), digoxigenin (Zischler), or bromodeoxyuridine (BrdUrd) or other modified bases including fluorescein-11-dUTP (Boehringer- Mannheim) (Kitazawa).
- a ligand-type reporter such as biotin (Weier), digoxigenin (Zischler), or bromodeoxyuridine (BrdUrd) or other modified bases including fluorescein-11-dUTP (Boehringer- Mannheim) (Kitazawa).
- the probe reporter groups are detected, in situ, by reaction of the hybridized probe with a secondary reporter molecule which (a) binds specifically and with high affinity to the probe ligands, and (b) contains a detectable reporter.
- the binding moiety of the secondary molecule may be avidin or streptavidin, for binding to biotinylated nucleotides, anti-digoxigenin antibody, for binding to digoxigenin- labeled nucleotides, and anti-BrdUrd antibody for binding to BrdUrd-labeled probe.
- the detectable reporter in the secondary molecule is typically a fluorescence label, but may also be a
- radiolabel for autoradiographic detection, an antibody, an enzyme, for colorimeteric or chemiluminescence
- RecA and RecA803 proteins for use in forming the RecA/probe complex used in the invention, are preferably isolated from overproducing strains, such as E. coli strains JC12772 and JC15369 (obtained from A.J. Clark and M. Madiraju). These strains contain the RecA coding sequences on a "runaway" replicating plasmid vector present at high copy numbers per cell.
- the RecA803 protein is a high-activity mutant of wildtype RecA
- the RecA proteins can be purchased from Pharmacia or purified using fast protein liquid chromatography (FPLC) on a hydroxylapatite column followed by an anion (Mono Q) exchange column.
- FPLC fast protein liquid chromatography
- Mono Q anion exchange column
- the standard assays for monitoring the protein purification include assay of 38,000-dalton RecA protein by SDS-polyacrylamide gel electrophoresis (PAGE)
- the SDS-PAGE profiles of the final Mono-Q-purified RecA and RecA803 proteins showed a single 38,000-dalton band, free of other cellular polypeptides as detected by silver staining.
- duplex nucleic acid in the biological structure of interest is reacted with a probe complex composed of RecA protein stably bound to the single-stranded probe.
- the complex is preferably prepared in a stabilized form in the presence of ATP ⁇ S.
- RecA protein coating of probes is normally carried out as detailed in Example 2. Briefly, the probe, whether double-stranded or single-stranded, is denatured by heating at 95-100oC for five minutes, then placed in an ice bath for 20 seconds to one minute followed by centrifugation at 0oC for approximately 20 sec, before use. Denatured probes can placed in a freezer at -20oC; preferably, however, they are immediately added to standard RecA coating reaction buffer containing ATP ⁇ S, at room temperature, and to this is added the RecA protein.
- RecA coating of probe is initiated by incubating probe-RecA mixtures at 37oC for 10-15 min.
- RecA protein concentration tested during reaction with probe varies depending upon probe size and the amount of added probe, and preferably ranges between about 2 to 25 ⁇ M.
- concentrations of ATP ⁇ S and RecA, respectively can be reduced to one-half those used with double-stranded probes (i.e. RecA and ATP ⁇ S concentration ratios are usually kept constant at a specific concentration of individual probe strand, depending on whether a single- or double-stranded probe is used).
- sequence-specific binding of the RecA/probe complex to the target duplex contained in a biological structure is achieved by adding the probe complex to the structure, under non-denaturing conditions, i.e., below the
- the target structure is washed to remove unbound probe complex.
- the probe reporter is a ligand, such as blotin
- the washed structure is contacted with a detectable reporter molecule, such as fluorescence-labeled avidin (FITC-avidin), to bind a detectable reporter to the target-bound probe.
- FITC-avidin fluorescence-labeled avidin
- the sample material is then further washed to remove unbound reporter molecule.
- wash procedures are suitable.
- the structure is visualized or otherwise viewed or detected by microscopy, fluorescence activated cell sorting, autoradiography, or the like, as for example described below.
- biotinylated probe are exemplary. Briefly, between 10- 20 ⁇ l probe complex is applied to a fixed preparation on a glass slide. Glass coverslips are placed over the hybridization areas and sealed, and the reactions are incubated in a moist container in a 37oc 7% CO 2 incubator for between 1-4 hours. Following incubation, the coverslip rubber cement seal is removed and the slides, with coverslips are washed several times to loosen and remove coverslips and remove unbound probe complex.
- counterstain such as propidium iodide, may be used to reduce photobleaching.
- the probe signal may be amplified by reacting the material on the slide with biotinylated anti-avidin antibody, followed by several wash steps and addition of FITC-avidin, to enhance the amount of
- the target structure is then examined for the presence of the reporter-labeled probe bound to the target nucleic acid, e.g., by fluorescence microscopy or laser scanning microscopy.
- Figure 1A shows FITC signal from in situ
- Chromosome X is estimated to contain about 5,000 copies/cell of the alpha satellite sequences (ONCOR literature).
- the biotinylated probe was reacted and post-labeled with FITC-avidin, as described above.
- denatured biotinylated chromosome X alpha satellite probe from the same stock used in the Figure 1A method was combined with formamide and dextran sulfate under traditional protocols and was hybridized to HEp-2 cell nuclei using prior art thermal denaturation (and renaturation) steps, with the results shown in Figure 1B.
- the procedure required several more hours for total preparation and hybridization time than the Figure 1A method, involved signal amplification, and generally gave a lower level of fluorescent signal through the nuclei.
- a chromosome-7 alpha satellite DNA/RecA complex is hybridized with HEp-2 interphase nuclei, as above.
- Chromosome 7 contains about 10 copies of the alpha satellite sequence probe used (ONCOR probe D7Z2).
- Figure 2A shows the target signal pattern after probe binding and FITC labeling, in accordance with the invention. As seen, the probe is localized in two distinct spots, presumably corresponding to the two chromosome 7's containing the alpha satellite sequence.
- Figure 2B shows the in situ hybridization probe bound target pattern achieved with the same probe, after amplification following prior art methods described above. Probe localization appears to be less specific than in the method of the invention. Further, total preparation and probe hybridization times were many hours longer.
- a third method demonstrates the ability to localize a target sequence within a nuclear volume relative to other targeted DNA sequences and/or the nuclear membrane, using a confocal laser scanning microscope (Zeiss LSM-10).
- Zeiss LSM-10 a confocal laser scanning microscope
- 100% methanol fixed HEp-2 cells were probed in suspension with the RecA/chromosome-X alpha satellite DNA probe complex, and labeled with FITC-avidin, as in Figure 1A above.
- Figure 3A shows the pattern of probe binding in a
- the method of the present invention also facilitates the detection of specific DNA sequences in metaphase chromosomes using native RecA-mediated fluorescence in situ hybridization. RecA coated biotinylated probe specific for human chromosome 1 alpha-satellite
- centromeric sequences was reacted with fixed HEp-2 cells on slides using the native RecA-mediated fluorescence in situ hybridization (Example 6). Before RecA-coated probe mix addition, cells were incubated at 60oC with 10 mM Tris-acetate (pH 7.5). This incubation step, below the denaturation temperature of cellular nucleic acid
- FITC hybridization signals were visualized using a Zeiss LSM in 488 nm argon-ion laser-scanning mode. The FITC hybridization signal is superimposed on the phase image of the
- RecA-mediated fluorescence In situ hybridization also facilitates the detection of unique gene sequences. RecA-coated biotinylated probes specific for the p53 gene (Oncor) were reacted with fixed cells in suspension using native fluorescence in situ hybridization reactions
- FITC probe signals were observed with a Zeiss LSM in 488 nm argon-ion laser-scanning mode.
- Figure 13 Figure 13A, 13C and 13E, FITC hybridization signals
- Figure 13B, 13D, and 13F phase images of cells in 13A, 13C and 13E, respectively
- Figure 13E and 13F HCC "Alexander" cells.
- the FITC FITC
- hybridization signals in Figure 13E are superimposed on the phase image of the cell in Figure 13F. Note that all hybridization signals are within cell nuclei and that FITC signals are often seen as pairs indicative of newly replicated DNA. The cell nucleus in Figure 13D appears to be in the process of dividing. The results
- the method of the present invention is also effective for the detection of unique gene sequences using fixed cells on slides.
- RecA-coated biotinylated p53 probe (Oncor) was reacted with fixed HCC cells on slides using a native
- Hybridization signals were apparent without any amplification of signal (i.e., extra signal amplification steps). Sample results are
- Figure 14 14A and 14C, FITC signals; 14B and 14D, phase images of cells seen in 14A and 14C, respectively. Note that all hybridization signals are within the nucleus and signals often appear as pairs. The position of the signal pairs in the nucleus shown, for example, in 14A and 14B suggests that in this nucleus the signal may represent a stage after DNA replication.
- the method in addition to the ability of the method of the present invention to be used for the detection of unique cellular gene sequences, the method can also be used for the detection of unique viral nucleic acid sequences.
- RecA-coated HBV DNA probes pAM6 and "BIOPROBE" were reacted with 100% methanol fixed cells in suspension using a native fluorescence in situ hybridization
- BIOPROBE strands average ⁇ 250bs and pAM6 single-strands average 300-500 bases in size. This difference might also be due to the fact that the probes contain HBV genomes of different serotypes ("BIOPROBE", adr-4; pAM6, adw). These results indicate that the method of the present Invention is useful for the detection of viral DNA sequences. Probes specific for any viral DNA target of Interest can be generated, RecA-protein coated, and used in the in situ hybridization method of the present invention. In addition to fluorescent detection a number of other detection methods might be used including, but not limited to, the following: chemiluminescence (Tropix Inc., Bedford MA) and radioactivity.
- the method of the present invention also has a good specificity of target detection.
- the specificity of the present method was examined as follows. Thirty ng of RecA coated single-stranded biotinylated HBV probe (pAM6) was reacted with ATCC HCC "Alexander" cells using a standard native in suspension fluorescence in situ hybridization protocol (Example 10).
- the specificity of the reaction signal for HBV targets was tested by adding 240 ng of either excess. RecA-coated single-stranded non-biotinylated homologous DNA, or 240 ng of nonhomologous competitor DNAs (Example 10). Biotinylated HBV probe and non-biotinylated HBV and ⁇ X174 competitor DNAs were nick-translated under the same conditions to insure that they were of a similar size (average 400-500 bs). Unlabeled human placenta DNA, (100 -120 bp fragments) was obtained from Oncor ("BLOCKIT DNA"). The results (Table l; Example 10) show that only homologous HBV DNA, not heterologous DNAs, specifically competes with the biotinylated HBV DNA probe signal.
- FIG. 16A Biotinylated HBV probe + excess unlabeled HBV DNA
- 16B Biotinylated HBV probe + excess unlabeled ⁇ X174 DNA
- 16C Biotinylated HBV probe + excess unlabeled human placenta DNA.
- FITC probe signals were observed with a Zeiss LSM in laser scanning mode. The observed FITC signals from the HBV probes are shown superimposed on the phase images of the cells. Note that it is clear from the signal and cell images that
- homologous HBV DNA specifically competes with the
- biotinylated HBV DNA probe signal but heterologous DNA does not compete.
- the RecA-facilitated native fluorescence in situ hybridization reaction detects specific nucleic acid targets that are homologous to labeled probe DNA.
- the invention provides a simplified and less time
- the method reduces artifacts by eliminating the need for a heat denaturation step and by reducing the need for signal enhancement, and allows more rapid and well defined detection of target sequences, including target sequences of low copy number.
- the method allows detection of low- copy sequences without the requirement to first amplify the sequences.
- the present method provides an important advantage for diagnostic gene mapping studies, as well as for diagnostic application involving unique or low-copy numbers of various pathogen sequences. These later applications are described in Section II below.
- the two probes could be labeled with different reporter groups, for example, fluorescent probes with different absorption or emission peaks, so that target sites containing both probes could be di ⁇ tinguised from sites containing one probe only.
- One general application of the invention is for diagnostic use in locating and visualizing a selected gene or regulatory sequence in a chromosome, and/or in a particular region of the chromosome.
- the target gene or sequence may be one which (a) generates a selected gene product, (b) is suspected of performing a critical cell- control function, such as that of a ribosome, an
- oncogene or a tumor suppressor gene
- (c) is related to a repeat sequence
- (d) is suspected of containing a genetic defect which prevents expression of an active gene product
- (e) may be related in chromosome position to a marker probe region with a known map position
- (f) may represent an integrated or non-integrated viral sequence, such as a DNA-hepatitis virus (e. g. , Hepatitis B Virus (HBV) (Ono, et al . ; Fujiyama, et al . ; Galibert, et al . ) in fixed chromatin or fixed virions.
- a DNA-hepatitis virus e. g. , Hepatitis B Virus (HBV) (Ono, et al . ; Fujiyama, et al . ; Galibert, et al . ) in fixed chromatin or fixed virions.
- HBV Hepatitis B Virus
- the diagnostic probe used in the method may be obtained, in some cases, from available plasmids, cosmids, viruses or other vectors, such as from human genomic libraries or may be chemically synthesized.
- the probe may be generated by sequencing enough of the protein product to generate probes for PCR amplification, and amplifying and tagging the corresponding gene sequence in genomic DNA using the probes in a PCR format.
- the amplified gene material can be purified by electrophoresis and used directly as the probe, or cloned into suitable vectors, using standard protocols.
- the nuclei are derived from cells staged in metaphase, using well known methods, then fixed and "dropped" on a glass slide to produce a
- chromosome material under investigation may be a spread of an isolated individual chromosome(s).
- Figure 4A shows a single metaphase chromosome 10 which may be in isolated form or part of a field
- the chromosome contains a known marker region 12 (gene site M) whose map location on the chromosome is known, and is suspected of containing a gene region of interest.
- the chromosome preparation on a slide is reacted with the probe complex, indicated at 14 in Figure 4A, and composed of a probe 16 coated with RecA protein, shown by circles at 18, and having biotin groups, indicated by vertical dashes at 26. Reaction of the probe complex with the chromosome material, in accordance with the invention, leads to homologous binding of the probe to a gene site S ( Figure 43) which is the target region of interest.
- the binding site S may be visualized, for site localization by a variety of methods.
- a second probe complex 22 composed of a probe 24 homologous to known region 12 (gene site M) and also containing biotin groups 26 is added to the chromosome preparation, and allowed to bind to its region of homology. After washing to remove unbound probe, the preparation is reacted with an FITC- avldin reporter 28, to label both sites on the chromosome with a fluorescent tag.
- the chromosomes are labeled with one or more specific fluorescent dyes. Indicated at 32, which give
- the chromosomes are also labeled with an avidin reporter 34 containing a
- excitation wavelength from that of the band staining fluorescent molecule(s).
- the chromosomes are visualized at one wavelength, as indicated at 36 in Figure 4D, and the location of the probe on the chromosomes site is visualized at a second excitation wavelength.
- reaction with one homologue is shown (4D) all homologous sequences would react with probe.
- the invention also provides an improved method for detecting a variety of chromosomal abnormalities.
- Figures 5-10 illustrate how the method can be applied to detecting various types of chromosome
- FIG. 5 frame A shows a normal chromosome 40a containing two linked marker regions 42 and 44 on one of the chromosome arms. The two regions in the chromosome are hybridized with individual probe
- one of the regions may be labeled with an avidin-linked fluorescence reporter specific against biotin groups on one probe complex, and the second region, labeled with a second fluorescence reporter carried on an anti-digoxigenin antibody specific against digoxigenin groups on the second probe complex.
- the first and second fluorescence reporters are indicated by open and solid circles, respectively in Figure 5 and in related Figures 6-10.
- the two regions are examined by fluorescence microscopy, at the appropriate excitation wavelengths, the two regions are localized by two distinguishable fluorescence spots (indicated by open and solid circles, in frame B). The two spots indicate the relative position of the two regions.
- Figure 6 illustrates, in frame A, a chromosome 40b which differs from chromosome 40a by a deletion of chromosome region 44.
- the mutation is seen, in frame B, as a single fluorescence spot at an excitation wavelength corresponding to region 42 only.
- Figure 7 illustrates, in frame A, a chromosome 40c which differs from chromosome 40a by an insertion between regions 42, 44 in the chromosome.
- the insertion is evidenced, in the fluorescence microscopy field seen in frame B, by a greater distance between the two
- Figure 8 illustrates, in frame A, a chromosome 40d which differs from chromosome 40a by a. duplication of the region 44.
- the duplication is seen, in Frame B, as a doublet at the excitation wavelength of the region 44 probe, as indicated.
- Figure 9 illustrates, in Frame A, a chromosome 40e which differs from chromosome 40a in that a segment containing region 44 has translocated to a second
- chromosome 48e The translocation is evidenced, in Frame B, by widely spaced fluorescence spots.
- the identity of chromosome 48e may be determined, as above, by staining the chromosomes with dyes which form characteristic metaphase banding patterns (or using chromosome 48 marker hybridization), as above.
- Figure 10 shows, in frame A, a chromosome 40f which differs from chromosome 40a in that the segment carrying regions 42, 44 has been inverted. The inversion is evidenced, in Frame B, by reversal of positions of the two fluorescence spots.
- Figure 12 shows the ability of the method of the present invention to detect specific chromosomal DNA sequences in metaphase chromosomes using native
- Example 6 describes the steps used to
- fluorescence in situ hybridization technique can be used to visualize sequence and gene position on nondenatured DNA in fixed chromosomes or chromatin.
- Figures 13 and 14 show the ability of RecA-mediated native fluorescence in situ hybridization detection of tumor suppressor gene sequences.
- the native RecA- mediated fluorescence in situ hybridization technique can be used to detect and visualize a unique single copy gene sequence in fixed cells in suspension ( Figures 13A to 13F) and on slides ( Figures 14A to 14D) without any signal amplification steps.
- the results show the detection of unique p53 sequences on chromosome 17 in ATCC HEp-2 and HCC "Alexander" cells (Examples 7 and 8).
- Figure 15 illustrates the ability of RecA-mediated native fluorescence in situ hybridization to detect HBV nucleic acid sequences in ATCC HCC "Alexander” cells in suspension.
- Figure 15 (Example 9) shows hybridization signals obtained using two different biotinylated HBV probes, "BIOPROBE” ( Figure 15A to 15B) and pAM6 ( Figure 15C to 15E).
- Viral targets were detected in ATCC HCC "Alexander” cells, known to contain HBV nucleic acid sequences, probed using the native fluorescence in situ hybridization technique in cell suspension.
- Hep-2 cells not infected with HBV nucleic acid sequences and probed with the same probes and techniques, did not show any hybridization signals.
- Figure 16 demonstrates the specificity of HBV target detection using native fluorescence in situ
- hybridization assay specifically identifies nucleic acid targets homologous to probe DNA ( Figure 16 and Table 1). This was demonstrated by showing that biotinylated pAM6 HBV DNA probe hybridization signal is specifically competed when reactions contain excess homologous
- hybridization signals e.g., with HBV probe DNA and HCC cells in suspension, are HBV specific.
- the RecA-mediated fluorescence in situ hybridization reactions of the present invention use RecA protein, cofactor, and 1-2 hour incubation times.
- Single-stranded probes in a broad size range work, including, but not limited to, average sizes of 100-200, 200-400, 300-500, 400-600, and up. Typically, size ranges above 100-200 are preferred and 300-500 are most preferred.
- Probes coated with RecA protein can be stored in the freezer for future use: probes stored for up to 7 days have been tested and gave good hybridization
- the hybridization reaction is capable of detecting single copy genes and sequences (e.g., p53), multiple copy sequences (e.g., alpha-satellite chromosome 1), and diagnostically
- RecA-protein mediated fluorescence in situ hybridization reactions are in general, more rapid than standard denatured fluorescence in situ hybridization assays.
- Some features of the present invention for native RecA-mediated fluorescence in situ hybridization include the following: native RecA-mediated fluorescence in situ hybridization can be used on IX PBS washed, 100% methanol fixed (or 70% ethanol fixed) cells in suspension; signals can be achieved with two hours, or less, of incubation with probe; the reaction is efficient -- for example, with 5 ⁇ ng probe and standard conditions, the reaction averages between 65-90% of cells with signal, depending upon the concentration of probe used; the reaction works with less than 50ng probe -- concentrations of probe in excess of 10 ng are preferred; a number of cofactors, including ATP ⁇ S, GTP ⁇ S, ATP, dATP and a combination of ATP ⁇ S and ADP, work in these reactions -- one embodiment employs ATP ⁇ S concentrations in the range of
- a wide range of RecA monomer:nucleotide ratios work veil, including 1:1, 1:0.8, 1:2 and 1:2.5 (a preferred embodiment utilizes 1:2); the amount of signal obtained with a Chromosome #1 alpha-satellite probe and native RecA-mediated fluorescence in situ hybridization on slides with HEp-2 cells are comparable to those obtained using a standard denatured fluorescence in situ hybridization technique; the reaction works in the presence of accessory proteins (e.g., single-strand binding protein (SSB), topoisomerase I and topoisomerase II); and when the reactions are carried out for samples fixed on slides the reaction efficiency is improved from an average range of 5-20% to 55-80%, by incubating slides in 10mM Tris-acetate buffer pH7.5 at 55-60oC for 30-45 min before adding RecA-coated probe mix.
- SSB single-strand binding protein
- topoisomerase I and topoisomerase II topoisomerase II
- Another general application of the method of the invention is for diagnostics, typically for detecting changes in chromosome ploidy or rearrangement, or
- FIG. 11A-11c for detection of virus infected cells, such as cell 50.
- Virion particles or integrated viral genomes contained in the cell are shown at 54.
- the cells e.g., blood cells, are obtained from the test subject, and treated to permeabilize the cellular structures, as discussed above.
- Figure 11A permeabilized cells
- Figure 11B permeabilized cells
- the probe signal may be enhanced. If necessary, by the amplification of reporter reagents described above, e.g., a biotinylated anti-avidin antibody, followed by a second fluorescence-labeled avidin reporter molecule.
- the labeled cells may be examined by fluorescence microscopy, to detect and localize infecting virus nucleic acid in the cells.
- FACS fluorescence activated cell sorting
- FIG. 1 shows a group of blood cells, such as cells 60, 62 passing through a capillary tube 64 in a FACS device equipped with a detector 66 for detecting fluorescence in individual cells passing through the detector region. Fluorescence labeled cells are indicated by dark shading in the figure. It is seen that the method provides rapid detection of Infected cells, for diagnostic purposes, and is capable of measuring level of infection and percentage of cells infected. Thus, for example, the method can be used to assess the progress of an anti-virus treatment, by measuring decreases in cell infection over the
- the FACS device may be further equipped with sorting apparatus for capturing fluorescence-labeled cells, to form a concentrate of infected cells.
- the concentrate in turn, can be used as a source of viral nucleic acid, for purposes of identifying and cloning the viral genome.
- RecA and RecA803 proteins were isolated from the overproducing strains JC12772 and JC15369 (obtained from A.J. Clark and M. Madiraju), or RecA was purchased from Pharmacia.
- RecA and RecA803 proteins were purified by
- oligonucleotide probe using a method modified from Cheng.
- Biotinylated chromosome X alpha satellite DNA probe was obtained from ONCOR (Gaither ⁇ burg, MD).
- Probe diluted in sterile MilliQ (Millipore) H 2 O was denatured in a 0.5 ml microcentrifuge tube in a 100oC heat block for 5 min, and the tube immediately placed in an ice water bath. Approximately 5 min prior to
- the probe hybridization mixture contains the following components in a broad range of concentrations and is combined in the order listed: 1 ⁇ l of 10X RecA reaction buffer [10X RecA reaction buffer:100mM Tris acetate pH 7.5 at 37oC, 20 mM magnesium acetate, 500 mM sodium acetate, 10 mM DTT and 50% glycerol (Cheng)); 1.5 ⁇ l ATP ⁇ S from 16.2 mM stock (3.24 and 1.62 mM stocks can also be used), (Pharmacia) (rATP, dATP, GTP ⁇ S, or a combination of ATP ⁇ S and ADP may be used in some reactions); 0.75 ⁇ l 20 mM magnesium acetate; 4-60 ng (or more in some reactions) of denatured probe in sterile ddH 2 O or TE (20 mM Tris HCl, pH7.5, and 0.1
- HEp-2 cells were originally derived from human male larynx epidermoid carcinoma tissue.
- HEp-2 is chromosome ploidy variable (Chen).
- the cells were cultured for 24 hours after seeding in DMEM (Whittaker or GIBCO-BRL) supplemented with 10% FBS, sodium pyruvate and Penstrep antibotics mix at 37oC under standard conditions.
- DMEM Woodtaker or GIBCO-BRL
- FBS fetal bovine serum
- sodium pyruvate sodium pyruvate
- Penstrep antibotics mix at 37oC under standard conditions.
- the cells were pelleted by low-speed centrifugation and gradually resuspended in 75 mM KCl in a 37oC water bath, and allowed to incubate for between 5 and 15 min for the desired amount of nuclear swelling to occur, followed by addition of 3:1 ice cold methanol:acetic acid and centrifugation at 6oC.
- nuclei was resuspended in 3:1 methanol:acetic acid at a concentration about 2 x loVml and is either dropped by pipette in 10 ⁇ l aliquots onto clean glass slides which were stored at -20oC, or the suspended nuclei or cell preparation are stored at -20oc for later use.
- Example 2 Ten ⁇ l of probe mixture/reaction from Example 2 was applied to the fixed preparation on glass slides. Glass coverslips were placed over the hybridization areas and sealed with rubber cement, and reactions were incubated enclosed in a moist container in a 37oC CO 2 incubator for between 1-4 hours. Following incubation, the rubber cement was removed and the slides were washed in coplin jars 3 times for 10 min each in 2X SSC (20X ssc: 3 M NaCl, 0.3 M sodium citrate, pH 7.0 is used in all SSC containing preparations in these assays) in a water bath at 37oC. Other wash conditions may also be used.
- 2X SSC 20X ssc: 3 M NaCl, 0.3 M sodium citrate, pH 7.0 is used in all SSC containing preparations in these assays
- the slides were placed in preblock solution [4X SSC, 0.1% Triton x-100, 5% carnation nonfat dry milk, 2% normal goat serum (Gibco), 0.02% sodium azide, pH 7.0] for 25 min at room temperature (RT), followed.by
- Antifade was applied [100 mg p-phenylenediamine dihydrochloride (Sigma P1519) in 10 ml PBS adjusted to pH 8 with 0.5 M carbonate-bicarbonate buffer (0.42 g NaHCO 3 adjusted to pH 9 with NaOH in 10 ml ddH 2 O) added to 90 mi glycerol, and 0.22 um filtered], and antifade mounting medium and coverslips were placed over the preparations.
- Antifade containing a counter ⁇ tain such as propidium iodide or DAPI was sometimes used instead of antifade alone.
- Figure 1A shows a fluorescence micrograph of a cell nucleus from the above preparation (no signal
- signal amplification may be performed as follows: Slides are washed for 5-10 min in 4X SSC and 0.1% Triton X-100 at RT to remove coverslips and
- Figure 1B shows a fluorescence micrograph of a cell nucleus from the above signal amplified preparation.
- satellite DNA was obtained from ONCOR.
- the probe was denatured and could be stored frozen for at least five weeks.
- 32 ng of denatured freshly thawed DNA probe in 16 ul (1:2, probe:H 2 O, 2 ng/ ⁇ l DNA) were added to the same amount of hybridization mixture and in the same order given in Example 2.
- the reaction contained a total of 21 ⁇ l.
- Probe was incubated on the nondenatured HEp-2 target cell nuclei (Example 3B) for 2.5 hours at 37oC in a CO 2 incubator followed by washing, blocking, and FITC-avidin incubation exactly as described for probe to chromosome X in Example 3B.
- the time to conduct the experiment, including the ethanol series treatment of the slide was approximately 5 hours.
- Figure 2A shows a fluorescence micrograph of a cell nucleus from the treated
- chromosome 7 probe under heat-denaturation conditions as in Example 3C. Briefly, 5 ng denatured probe to
- chromosome 7 alpha satellite DNA was combined with hybridization buffer (Hybrisol V1, ONCOR, as in Figure 1B) and denatured using ONCOR protocols. 7 ⁇ l of the probe mixture was hybridized with HEp-2 cell nuclei for 16 hours and the reaction treated according to ONCOR protocols, including signal amplification.
- Figure 2B shows a fluorescence photomicrograph of the treated denatured nuclei.
- Oncor probe stock (also used in Example 2) vas diluted and denatured at 100°C for 5 min, immediately placed in an ice-water bath (for approximately 15 min) and stored in a -20oC freezer briefly (about 5 min) before addition to the hybridization mixture.
- the hybridization mixture was combined in the following order (components, concentrations, and mixtures are described in detail in Example 2): 1 ⁇ l 10X RecA reaction buffer (see Example 2), 1.5 ⁇ l ATP ⁇ S (16.2 mM stock, Pharmacia), 0.75 ⁇ l magnesium acetate (20 mM stock), 12 ⁇ l of
- denatured probe containing 60 ng in a 1:2
- HEp-2 cells were fixed in 100% methanol (or other appropriate solutions) at -20oC at a concentration of approximately 2.5 x 10 6 /ml.
- About 0.5 ml of the suspended cells (1.25 x 10 6 ) were centrifuged in a "TOMY" centrifuge set at 6oC in a 1.5 ml microcentrifuge tube and
- the completed probe mixture was mixed with the pellet, and the tube placed in a 37oC water bath for 1.5- 2.5 hours. Incubation was stopped by addition of 250 ⁇ l 2 X SSC (prewarmed to 37oC) followed by centrifugation. The pellet was resuspended in 2 X SSC (prewarmed to 37oC) and incubated for 5 min at 37oC.
- the Figure 3A photomicrograph shows a dividing fixed HEp-2 cell nucleus, as viewed with a zeiss LSM-10
- chromosome 1 alpha-satellite centromeric sequence probe mix was prepared.
- the 60oC preincubation treatment does not denature target DNAs but it does improve the efficiency of native RecA-mediated fluorescence in situ hybridization
- the DNA probe was heat denatured at 100oc in 5.16 ⁇ l dd H 2 O for 5 minutes, quick-cooled in an ice-water bath, centrifuged at 4oC in a "TOMY" microcentrifuge for 20 seconds to collect the liquid, and then immediately added to a mixture containing the other reaction components.
- Chromosome 1 probe was coated with RecA protein in a reaction mixture containing 1 ⁇ l of 10 X acetate reaction buffer (Cheng et al, 1988), 1.5 ⁇ l of 16.2 mM ATP ⁇ S
- Figure 12 shows the hybridization signal from the fixed HEp-2 metaphase chromosomes with the RecA-coated, biotinylated, nick-translated probe to human chromosome 1 alpha-satellite centromeric sequences, under these conditions, 73% of the cell interphase nuclei including chromosome spreads showed signals.
- the chromosome 1 alpha satellite specifically hybridized with the
- Figures 13A and 13B First conditions: Figures 13A and 13B.
- Example 7A All cells and cell washes were identical to Example 7A. Probe was reacted with RecA as described above with the exception that the 0.02M MgOAc was omitted and 0.75 ⁇ l of ddH 2 O was added instead. Under these conditions, 40% of the cells had bright hybridization signals
- Example 7A All cell washes were identical to Example 7A. Probe was reacted as described above (Example 7A) with the exception that probe coating mix contained 1.5 ⁇ l 16.2 mM ATP ⁇ S, the reaction mix was incubated for 13 minutes at 37oC before addition of 0.5 ⁇ l 0.2mM MgOAc, RecA-coated probe was added to 1.25 x 10 6 100% methanol fixed ATCC HCC "Alexander" cells and reacted for 3 hr 20 minutes at 37oC. Cell washing after probe reaction was as described in Example 7A except that cells were reacted with 50 ⁇ l of filtered preblock containing 10.0 ⁇ g/ml FITC-Avidin. Under these conditions, 82% of the cells had bright hybridization signals ( Figures 13E and 13F).
- Example 6 except that 1.5 ⁇ l of 3.24 mM ATP ⁇ S, 0.59 ⁇ l of 5.51 ⁇ g/ ⁇ l RecA and 0.5 ⁇ l containing 2U topoisomerase II (United States Biochemicals Corp., Cleveland OH) were added, and half as much denatured probe was added [2.5 ⁇ l (25 ng probe) in 3.66 ⁇ l dd H 2 O].
- HBV Nucleic Acid Sequences in ATCC HCC "Alexander" Cells in Suspension 1 x 10 6 of 100% methanol fixed HCC cells/reaction are placed in 0.5 ml sterile microfuge tubes, centrifuged for 30 seconds at 2 K rpm in a "TOMY” microcentrifuge at 4oC, and the supernatant removed. 200 ⁇ l of ice-cold 70% EtOH is added, the treated cells are centrifuged at 4oC, the supernatant removed, the dehydration step repeated and the sample centrifuged as above using, sequentially, 85% and 100% iced-cold EtOH.
- the cells are centrifuged and resuspended in 200 ⁇ l IX acetate reaction buffer (same as standard RecA acetate reaction buffer except, minus the glycerol), centrifuged, and resuspended in same IX acetate reaction buffer (minus glycerol). Immediately before the addition of the probe reaction mixture, the cells are incubated at 37oC for 10 minutes, centrifuged at room temperature and the
- Biotin-labeled HBV-specific "BIOPROBE” was obtained from Enzo Diagnostics, Inc. (New York NY) . This
- nick-translated probe is biotinylated with bio-n-dUTP, contains the whole HBV genome (adr4 serotype) and double-stranded probe fragments average 250 bp in size.
- pAM6 A second probe, pAM6, was obtained from the ATCC.
- pAM6 contains the whole HBV genome (adw serotype) in plasmid pBR322.
- pAM6 was labeled with bio-14-dATP by nick-translation with the BRL Nick-translation System as described in Example 6. Heat denatured single-stranded probe averaged 300-500 bases in size.
- Both HBV probes were coated with RecA protein a 10 ⁇ l reaction containing 1 ⁇ l 10X acetate reaction buffer (Cheng, et al, 1988), 1.5 ⁇ l 3.24 mM ATP ⁇ S, 0.75 ⁇ l 20 mM MgOAc, 0.53 ⁇ l 5.5 ⁇ g/ ⁇ l RecA, and heat denatured probe [0.83 ⁇ l "BIOPROBE" (60 ⁇ g/ ⁇ l) was in 5.39 ⁇ l ddH 2 O; 5 ⁇ l pAM6 probe (10 ⁇ g/ ⁇ l) was in 1.22 ⁇ l ddH 2 O]. Probe coating reactions were incubated at 37oC for 10 minutes, then 0.5 ⁇ l of 0.2M MgOAc stock solution was added and the probe mixes were added to the prepared cell pellets.
- the prepared probe mixes were individually added to separate cell samples and incubated at 37oC in waterbath for 2 hours. The reaction was stopped by the addition of 250 ⁇ l 1.75X SSC (pH 7.4) at 37oC. Each sample was mixed, the cells pelleted and the supernatant removed. 250 ⁇ l of 1.75X ssc was added and the samples incubated at 37oC for 5 minutes. This wash was then repeated. The cells were pelleted and to each sample 300 ⁇ l of filtered preblock vas added. The samples were incubated at room temperature for 20 minutes. The cells were pelleted and the preblock removed.
- Pellet cells remove supernatant, add 250 ⁇ l 4X ssc.
- the cells were pelleted, supernatant removed, the pellet air dried, and 20 ⁇ l of antifade added.
- the samples were then examined using a Zeiss LSM.
- Figures 15A and 15B show the results of the above hybridizations using "BIOPROBE”: 81% of the cells had hybridization signals.
- Figures 15C to 15E show the results of the above hybridizations using the pAM6 probe: 95% of the cells had hybridization signals.
- unlabeled DNAs contained dATP in place of bio-14-dATP.
- Each competition reaction used 1 X 10 6 100% methanol fixed cells and contained 30 ng of biotinylated pAM6 HBV probe DNA and 240 ng of competitor DNA. Biotinylated HBV probe DNA and unlabeled competitor DNAs were coated with RecA in separate reactions. After RecA coating, the Mg ++ ion concentration of each reaction was adjusted by adding 0.5 ⁇ l of 0.2mM MgOAc per 10 ⁇ l of coating reaction.
- RecA-coated biotinylated HBV probe and competitor DNA was 21 ⁇ l.
- biotinylated pAM6 probe was coated with RecA in a reaction containing 4 ⁇ l of 10X acetate reaction buffer (Cheng, et al, 1988), 6 ⁇ l of 3.24 mM ATP ⁇ S, 3 ⁇ l of 20 mM MgOAc, 3.16 ⁇ l of 2.2 ⁇ g/ ⁇ l RecA, and 12 ⁇ l of 10 ng/ ⁇ l-bio-pAM6 probe (which was heat denatured in 11.84 ⁇ l ddH 2 O).
- Each competitor RecA DNA probe coating mix contained 1 ⁇ l of 10X acetate reaction buffer, 1.5 ⁇ l 3.24 mM
- ATP ⁇ S 0.75 ⁇ l 20 mM MgOAc, 1.25 ⁇ l 11.05 ⁇ g/ ⁇ l RecA, and either 4.8 ⁇ l of 50 ng/ ⁇ l competitor DNA heat denatured in 0.7 ⁇ l ddH 2 O (non-biotinylated ⁇ X174 or non- biotinylated pAM6), or 2.4 ⁇ l of 5 ⁇ g/ ⁇ l non-biotinylated placenta DNA ("BLOCKIT";Oncor) heat denatured in 3.1 ⁇ l ddH 2 O.
- Probes were coated with RecA for 15 minutes at 37oC and then 0.5 ⁇ l of 0.2M MgOAc was added/10 ⁇ l DNA
- the -20oC stored methanol-fixed cells were prepared for fluorescence in situ hybridization as previously described in Example 9 by dehydrating through a series of cold EtOH washes, followed by 2 times washes in 1X acetate reaction buffer (minus glycerol). cells were incubated in the last wash buffer for 10 minutes at 37oc before buffer was removed and the 21 ⁇ l of RecA-coated
- biotinylated probe and competitor DNA mixtures were added to the cell pellets.
- Probes were reacted with cells in a 37oC water bath for 3 hrs. Reactions were stopped by addition of 250 ⁇ l 1.75X SSC (pH7.4) at 37oc, mixed, centrifuged. at room temperature (R T ) to pellet cells, and supernatant removed. Cells were washed twice with 250 ⁇ l 1.75X SSC at 37oC-for 5 minutes then spun down and the supernatant removed.
- FITC-Avidin was removed after cells were pelleted by centrifugation. Reacted cells were washed consecutively in 4X SSC (pH7.4) mixed gently with the cells, 250 ⁇ l 4X SSC + 0.1% "TRITON X-100" and 250 ⁇ l 4X SSC. After each wash, cells were pelleted and the wash liquid removed.
- FITC signals with the other competing DNAs were easily visible using the fluorescence microscope alone, the signals with this sample were only visible when 488 nm argon-ion laser illumination was used.
- FIGS 16A to 16C are from the competition experiments described in Table l. in Figure 16: 16A, Biotinylated HBV probe + excess unlabeled HBV probe DNA; 16B, Biotinylated HBV probe + excess unlabeled ⁇ X174 DNA; 16C, Biotinylated HBV probe + excess unlabeled human placenta DNA ("BLOCKIT"; oncor). FITC probe signals were observed with a Zeiss LSM in laser scanning mode.
- the observed FITC signals from the HBV probes are shown superimposed on the phase images of the cells.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92918705A EP0614492B1 (en) | 1991-09-04 | 1992-09-03 | In situ hybridization method |
KR1019940700703A KR100245283B1 (en) | 1991-09-04 | 1992-09-03 | In situ hybridization method |
US08/199,326 US5719023A (en) | 1991-09-04 | 1992-09-03 | In situ hybridization method |
DE69215533T DE69215533T2 (en) | 1991-09-04 | 1992-09-03 | IN-SITU HYBRIDIZATION METHOD |
AU25007/92A AU664045B2 (en) | 1991-09-04 | 1992-09-03 | In situ hybridization method |
JP5505108A JP2819830B2 (en) | 1991-09-04 | 1992-09-03 | In situ hybridization method |
NO940746A NO940746L (en) | 1991-09-04 | 1994-03-03 | In situ hybridization method |
FI941015A FI941015A (en) | 1991-09-04 | 1994-03-03 | In situ hybridization procedure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/755,291 US5506098A (en) | 1991-09-04 | 1991-09-04 | In situ hybridization method |
US07/755,291 | 1991-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993005177A1 true WO1993005177A1 (en) | 1993-03-18 |
Family
ID=25038542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/001128 WO1993005177A1 (en) | 1991-09-04 | 1992-09-03 | In situ hybridization method |
Country Status (13)
Country | Link |
---|---|
US (2) | US5506098A (en) |
EP (1) | EP0614492B1 (en) |
JP (1) | JP2819830B2 (en) |
KR (1) | KR100245283B1 (en) |
AT (1) | ATE145674T1 (en) |
AU (1) | AU664045B2 (en) |
CA (1) | CA2116214C (en) |
DE (1) | DE69215533T2 (en) |
DK (1) | DK0614492T3 (en) |
ES (1) | ES2094928T3 (en) |
FI (1) | FI941015A (en) |
NO (1) | NO940746L (en) |
WO (1) | WO1993005177A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024652A1 (en) * | 1992-05-22 | 1993-12-09 | Cristoph Cremer | Process for preparing and hybridizing specific probes |
WO1995003428A1 (en) * | 1993-07-20 | 1995-02-02 | University Of Massachusetts Medical Center | In vivo nucleic acid hybridization method |
WO1995018236A1 (en) * | 1993-12-28 | 1995-07-06 | Daikin Industries, Ltd. | IN-SITU HYBRIDIZATION METHOD USING RecA PROTEIN AND RecA PROTEIN HAVING MARKER OR LIGAND FOR USE IN SAID METHOD |
WO1998008975A1 (en) * | 1996-08-29 | 1998-03-05 | Daikin Industries, Ltd. | Methods for targeting, enriching, detecting and/or isolating target nucleic acid sequence using reca-like recombinase |
WO1998037231A2 (en) * | 1997-02-22 | 1998-08-27 | Ruprecht-Karls-Universität Heidelberg | Marking of nucleic acids with special probe mixtures |
US5948653A (en) * | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US7229767B2 (en) | 2001-03-27 | 2007-06-12 | University Of Delaware | Genomics applications for modified OLIGO nucleotides |
US7468244B2 (en) | 2001-09-27 | 2008-12-23 | University Of Delaware | Polymorphism detection and separation |
WO2011161459A1 (en) | 2010-06-23 | 2011-12-29 | Reckitt Benckiser N.V. | Machine dishwashing compositions and methods |
US8551739B2 (en) | 1994-12-19 | 2013-10-08 | Memorial Sloan-Kettering Cancer Center | Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase |
US20220243281A1 (en) * | 2019-05-28 | 2022-08-04 | Case Western Reserve University | Compositions and methods for preserving dna methylation |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100245284B1 (en) * | 1990-05-07 | 2000-03-02 | 이노우에 노리유끼 | Diagnostic applications of double d-loop formation |
US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
US5750340A (en) * | 1995-04-07 | 1998-05-12 | University Of New Mexico | In situ hybridization solution and process |
US6022689A (en) * | 1995-04-07 | 2000-02-08 | University Of New Mexico | Situ hybridization slide processes |
FR2755148B1 (en) * | 1996-10-31 | 1999-01-29 | Calvo Fabien | METHOD FOR HIGHLIGHTING THE CONDITION OF A MALIGNANT CELL AND TREATMENT METHOD |
JP3891620B2 (en) * | 1996-11-14 | 2007-03-14 | 株式会社アイシン・コスモス研究所 | Nucleic acid probe molecule having a hairpin structure, and nucleic acid detection method using the nucleic acid probe molecule |
US5948617A (en) * | 1997-06-13 | 1999-09-07 | Biospeparations, Inc. | Methods of in situ hybridization |
US6194146B1 (en) | 1997-06-13 | 2001-02-27 | Bioseparations, Inc. | Situ and in vitro hybridization method and buffer |
AU8162598A (en) * | 1997-06-25 | 1999-01-04 | Life Technologies, Inc. | Improved method for isolating and recovering target dna or rna molecules having a desired nucleotide sequence |
US6289229B1 (en) | 1998-01-20 | 2001-09-11 | Scimed Life Systems, Inc. | Readable probe array for in vivo use |
DE69835342T2 (en) | 1998-04-27 | 2007-08-23 | Corning Inc. | Method for storing biological samples with the aid of a redrawn capillary store |
US6884626B1 (en) | 1998-04-27 | 2005-04-26 | Corning Incorporated | Redrawn capillary imaging reservoir |
US6350618B1 (en) * | 1998-04-27 | 2002-02-26 | Corning Incorporated | Redrawn capillary imaging reservoir |
WO1999060163A1 (en) * | 1998-05-18 | 1999-11-25 | Igenex, Inc. | In situ hybridization method for detecting target nucleic acid |
US6762061B1 (en) | 1998-07-03 | 2004-07-13 | Corning Incorporated | Redrawn capillary imaging reservoir |
JP2002524091A (en) | 1998-08-21 | 2002-08-06 | ナックスコー・インコーポレイテッド | Assays using immobilized crosslinkable nucleic acids |
US6581011B1 (en) * | 1999-06-23 | 2003-06-17 | Tissueinformatics, Inc. | Online database that includes indices representative of a tissue population |
US6611833B1 (en) * | 1999-06-23 | 2003-08-26 | Tissueinformatics, Inc. | Methods for profiling and classifying tissue using a database that includes indices representative of a tissue population |
CA2381732A1 (en) * | 1999-08-21 | 2001-03-01 | John S. Fox | High sensitivity biomolecule detection with magnetic particles |
US20010016317A1 (en) * | 1999-09-13 | 2001-08-23 | Dolores M. Berger | Method for providing long term stability to cells for diagnostic testing |
US20040224421A1 (en) * | 2000-06-15 | 2004-11-11 | Deweerd Herman | Bi-directional scanning method |
EP1172445A1 (en) * | 2000-07-14 | 2002-01-16 | Praenadia GmbH | A method for direct genetic analysis of target cells by using fluorescence probes |
US7754155B2 (en) * | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
US20030175818A1 (en) * | 2002-03-15 | 2003-09-18 | Ross Amelia A. | Devices and methods for isolating and recovering target cells |
WO2003091455A1 (en) * | 2002-04-23 | 2003-11-06 | U.S.Genomics, Inc. | Compositions and methods related to two-arm nucleic acid probes |
WO2004007692A2 (en) * | 2002-07-17 | 2004-01-22 | U.S.Genomics, Inc. | Methods and compositions for analyzing polymers using chimeric tags |
US20040180345A1 (en) * | 2003-03-14 | 2004-09-16 | Ingeneus Corporation | Pre-incubation method to improve signal/noise ratio of nucleic acid assays |
EP1649028B1 (en) * | 2003-07-25 | 2012-08-22 | Genvec, Inc. | Adenoviral vector-based vaccines |
JP2007501003A (en) * | 2003-08-01 | 2007-01-25 | ユー.エス. ジェノミクス, インコーポレイテッド | Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions |
JP2007529758A (en) * | 2004-03-19 | 2007-10-25 | ユー.エス. ジェノミクス, インコーポレイテッド | Compositions and methods for single molecule detection |
CA2589602A1 (en) * | 2004-09-01 | 2006-04-13 | Genvec, Inc. | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
KR100760525B1 (en) * | 2006-04-13 | 2007-10-04 | 김재만 | Kit and method for quantitatively detecting multiple pathogens without gene amplification |
US20100294665A1 (en) * | 2007-07-12 | 2010-11-25 | Richard Allen | Method and system for transferring and/or concentrating a sample |
JP5298134B2 (en) | 2007-11-01 | 2013-09-25 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Immunosuppressive polypeptides and nucleic acids |
SG11202102255VA (en) * | 2018-09-05 | 2021-04-29 | Readcoor Llc | Methods and systems for therapeutic agent analysis |
CN113741375B (en) * | 2021-09-18 | 2023-02-03 | 中国科学院近代物理研究所 | Special production terminal control system for heavy ion microporous membrane |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985005685A1 (en) * | 1984-06-01 | 1985-12-19 | National Biomedical Research Foundation | Catalyzed nucleic acid hybridization using enzymatic reagent |
WO1987001730A1 (en) * | 1985-09-18 | 1987-03-26 | Yale University | RecA NUCLEOPROTEIN FILAMENT AND METHODS |
EP0322311A2 (en) * | 1987-12-21 | 1989-06-28 | Applied Biosystems, Inc. | Method and kit for detecting a nucleic acid sequence |
WO1991017267A1 (en) * | 1990-05-07 | 1991-11-14 | Sri International | Process for nucleic acid hybridization and amplification |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4888274A (en) * | 1985-09-18 | 1989-12-19 | Yale University | RecA nucleoprotein filament and methods |
KR100245284B1 (en) * | 1990-05-07 | 2000-03-02 | 이노우에 노리유끼 | Diagnostic applications of double d-loop formation |
-
1991
- 1991-09-04 US US07/755,291 patent/US5506098A/en not_active Expired - Fee Related
-
1992
- 1992-09-03 CA CA002116214A patent/CA2116214C/en not_active Expired - Fee Related
- 1992-09-03 US US08/199,326 patent/US5719023A/en not_active Expired - Fee Related
- 1992-09-03 KR KR1019940700703A patent/KR100245283B1/en not_active IP Right Cessation
- 1992-09-03 EP EP92918705A patent/EP0614492B1/en not_active Expired - Lifetime
- 1992-09-03 DK DK92918705.2T patent/DK0614492T3/en active
- 1992-09-03 ES ES92918705T patent/ES2094928T3/en not_active Expired - Lifetime
- 1992-09-03 AU AU25007/92A patent/AU664045B2/en not_active Ceased
- 1992-09-03 WO PCT/JP1992/001128 patent/WO1993005177A1/en active IP Right Grant
- 1992-09-03 AT AT92918705T patent/ATE145674T1/en not_active IP Right Cessation
- 1992-09-03 DE DE69215533T patent/DE69215533T2/en not_active Expired - Fee Related
- 1992-09-03 JP JP5505108A patent/JP2819830B2/en not_active Expired - Fee Related
-
1994
- 1994-03-03 NO NO940746A patent/NO940746L/en not_active Application Discontinuation
- 1994-03-03 FI FI941015A patent/FI941015A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985005685A1 (en) * | 1984-06-01 | 1985-12-19 | National Biomedical Research Foundation | Catalyzed nucleic acid hybridization using enzymatic reagent |
WO1987001730A1 (en) * | 1985-09-18 | 1987-03-26 | Yale University | RecA NUCLEOPROTEIN FILAMENT AND METHODS |
EP0322311A2 (en) * | 1987-12-21 | 1989-06-28 | Applied Biosystems, Inc. | Method and kit for detecting a nucleic acid sequence |
WO1991017267A1 (en) * | 1990-05-07 | 1991-11-14 | Sri International | Process for nucleic acid hybridization and amplification |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024652A1 (en) * | 1992-05-22 | 1993-12-09 | Cristoph Cremer | Process for preparing and hybridizing specific probes |
US5888734A (en) * | 1992-05-22 | 1999-03-30 | Cremer; Christoph | Method for preparing and hybridizing specific probes |
US5728527A (en) * | 1993-07-20 | 1998-03-17 | University Of Massachusetts Medical Center | Detection of hybridized oligonocleotide probes in living cells |
WO1995003428A1 (en) * | 1993-07-20 | 1995-02-02 | University Of Massachusetts Medical Center | In vivo nucleic acid hybridization method |
EP0687738A4 (en) * | 1993-12-28 | 1999-05-19 | Daikin Ind Ltd | IN-SITU HYBRIDIZATION METHOD USING RecA PROTEIN AND RecA PROTEIN HAVING MARKER OR LIGAND FOR USE IN SAID METHOD |
EP0687738A1 (en) * | 1993-12-28 | 1995-12-20 | Daikin Industries, Ltd. | IN-SITU HYBRIDIZATION METHOD USING RecA PROTEIN AND RecA PROTEIN HAVING MARKER OR LIGAND FOR USE IN SAID METHOD |
WO1995018236A1 (en) * | 1993-12-28 | 1995-07-06 | Daikin Industries, Ltd. | IN-SITU HYBRIDIZATION METHOD USING RecA PROTEIN AND RecA PROTEIN HAVING MARKER OR LIGAND FOR USE IN SAID METHOD |
US5965361A (en) * | 1993-12-28 | 1999-10-12 | Daikin Industries, Ltd. | In-situ hybridization method using RecA protein and RecA protein having marker or ligand for use in said method |
US8551739B2 (en) | 1994-12-19 | 2013-10-08 | Memorial Sloan-Kettering Cancer Center | Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase |
WO1998008975A1 (en) * | 1996-08-29 | 1998-03-05 | Daikin Industries, Ltd. | Methods for targeting, enriching, detecting and/or isolating target nucleic acid sequence using reca-like recombinase |
US6335164B1 (en) | 1996-08-29 | 2002-01-01 | Daikin Industries, Ltd. | Methods for targeting, enriching, detecting and/or isolating target nucleic acid sequence using RecA-like recombinase |
WO1998037231A2 (en) * | 1997-02-22 | 1998-08-27 | Ruprecht-Karls-Universität Heidelberg | Marking of nucleic acids with special probe mixtures |
WO1998037231A3 (en) * | 1997-02-22 | 1998-12-10 | Univ Heidelberg | Marking of nucleic acids with special probe mixtures |
US5948653A (en) * | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US6200812B1 (en) | 1997-03-21 | 2001-03-13 | Sri International | Sequence alterations using homologous recombination |
US6074853A (en) * | 1997-03-21 | 2000-06-13 | Sri | Sequence alterations using homologous recombination |
US7229767B2 (en) | 2001-03-27 | 2007-06-12 | University Of Delaware | Genomics applications for modified OLIGO nucleotides |
US7468244B2 (en) | 2001-09-27 | 2008-12-23 | University Of Delaware | Polymorphism detection and separation |
WO2011161459A1 (en) | 2010-06-23 | 2011-12-29 | Reckitt Benckiser N.V. | Machine dishwashing compositions and methods |
US20220243281A1 (en) * | 2019-05-28 | 2022-08-04 | Case Western Reserve University | Compositions and methods for preserving dna methylation |
Also Published As
Publication number | Publication date |
---|---|
JPH06510200A (en) | 1994-11-17 |
DK0614492T3 (en) | 1997-06-02 |
EP0614492A1 (en) | 1994-09-14 |
ES2094928T3 (en) | 1997-02-01 |
NO940746D0 (en) | 1994-03-03 |
FI941015A0 (en) | 1994-03-03 |
CA2116214A1 (en) | 1993-03-05 |
US5719023A (en) | 1998-02-17 |
KR100245283B1 (en) | 2000-03-02 |
DE69215533D1 (en) | 1997-01-09 |
JP2819830B2 (en) | 1998-11-05 |
AU664045B2 (en) | 1995-11-02 |
CA2116214C (en) | 1998-12-22 |
US5506098A (en) | 1996-04-09 |
NO940746L (en) | 1994-03-03 |
FI941015A (en) | 1994-05-03 |
AU2500792A (en) | 1993-04-05 |
DE69215533T2 (en) | 1997-03-20 |
ATE145674T1 (en) | 1996-12-15 |
EP0614492B1 (en) | 1996-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU664045B2 (en) | In situ hybridization method | |
Lichter et al. | [22] Detection of chromosomal aberrations by means of molecular cytogenetics: Painting of chromosomes and chromosomal subregions and comparative genomic hybridization | |
US5985549A (en) | Non-isotopic in-situ hybridization method for detection of nucleic acids | |
DK2576830T3 (en) | Methods for in situ detection of nucleotide sequences | |
EP0430402A2 (en) | Methods and compositions for chromosome-specific staining | |
US10400275B2 (en) | Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample | |
US5965361A (en) | In-situ hybridization method using RecA protein and RecA protein having marker or ligand for use in said method | |
Lichter et al. | Molecular analysis of chromosome aberrations: in situ hybridization | |
US6242184B1 (en) | In-situ hybridization of single-copy and multiple-copy nucleic acid sequences | |
IE920547A1 (en) | Chromosome-specific staining to detect genetic¹rearrangements | |
CA2021489C (en) | Methods and compositions for chromosome-specific staining | |
Trotter et al. | highly resolved detection of long non-coding RNAs in Situ | |
Cannizzaro et al. | Fluorescent in situ hybridization (FISH) for DNA probes in the interphase and metaphase stages of the cell cycle | |
Zitzelsberger et al. | Multicolor FISH techniques for the detection of inter-and intrachromosomal rearrangements | |
Smajkan | Applications of Fluorescent in situ hybridization (FISH) | |
Harrison et al. | Molecular cytogenetics in childhood leukemia | |
Schwanitz et al. | Fluorescence in situ hybridization | |
Ghaffari | Development and Application of Comparative Genomic Hybridisation (CGH) | |
du Sart et al. | The technique of in situ hybridization: principles and applications | |
Isa | Optimization and Application of Chromosome In Situ Suppression Hybridization. | |
Inam et al. | Fluorescent in situ Hybridization | |
Szeles | Visualizing EBV Expression Patterns by FISH | |
White | Molecular cytogenetic evaluation of uveal melanoma cell lines and archival tissue | |
Acar | Optimisation and Application of Fluorescence In Situ Hybridization in Selected Leukaemias | |
CA2929932A1 (en) | Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2116214 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 941015 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992918705 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08199326 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992918705 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992918705 Country of ref document: EP |